These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26153638)

  • 1. Current and future strategies in nonclear-cell metastatic renal cell carcinoma.
    Albiges L; Escudier B
    Curr Opin Urol; 2015 Sep; 25(5):367-73. PubMed ID: 26153638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
    Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should clinicians address intratumour heterogeneity in clear cell renal cell carcinoma?
    Soultati A; Stares M; Swanton C; Larkin J; Turajlic S
    Curr Opin Urol; 2015 Sep; 25(5):358-66. PubMed ID: 26125509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
    Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
    Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Third-Line Treatment Options for Kidney Cancer.
    Posadas EM; Limvorasak S; Figlin RA
    Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
    [No Abstract]   [Full Text] [Related]  

  • 6. Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma.
    Raspollini MR; Montagnani I; Montironi R; Castiglione F; Martignoni G; Cheng L; Lopez-Beltran A
    J Clin Pathol; 2018 May; 71(5):467-471. PubMed ID: 29317515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies.
    Suárez C; Díaz-Mejía N; Morales-Barrera R; González M; Mateo J; Carles J
    Curr Opin Urol; 2021 May; 31(3):242-248. PubMed ID: 33742977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncotargets in different renal cancer subtypes.
    Moch H; Montironi R; Lopez-Beltran A; Cheng L; Mischo A
    Curr Drug Targets; 2015; 16(2):125-35. PubMed ID: 25619751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
    Saleeb RM; Farag M; Lichner Z; Brimo F; Bartlett J; Bjarnason G; Finelli A; Rontondo F; Downes MR; Yousef GM
    Mol Oncol; 2018 Oct; 12(10):1673-1688. PubMed ID: 29896907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
    van der Mijn JC; Mier JW; Broxterman HJ; Verheul HM
    Drug Resist Updat; 2014; 17(4-6):77-88. PubMed ID: 25457974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key sunitinib-related biomarkers for renal cell carcinoma.
    Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
    Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
    Wright I; Kapoor A
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
    Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
    Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
    Schneider M; Schüler J; Höfflin R; Korzeniewski N; Grüllich C; Roth W; Teber D; Hadaschik B; Pahernik S; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Aug; 32(6):877-84. PubMed ID: 24929890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving therapeutic targets in renal cell carcinoma.
    Singer EA; Gupta GN; Marchalik D; Srinivasan R
    Curr Opin Oncol; 2013 May; 25(3):273-80. PubMed ID: 23455028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Renal cell carcinoma].
    Tomita Y
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
    Gross-Goupil M; Massard C; Ravaud A
    Curr Urol Rep; 2012 Feb; 13(1):16-23. PubMed ID: 22139625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.